The company can now initiate its phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy. NCX 470 is Nicox’s lead dual-mechanism bimatoprost ...
Abstract: We present HARP (HAnd Reconstruction and Personalization), a personalized hand avatar creation approach that takes a short monocular RGB video of a human hand as input and reconstructs a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback